From the Cardiovascular Research Laboratories, Division of Cardiology,
University of Pittsburgh Medical Center, Pittsburgh, Pa (T.K., D.M.M., J.J.W.,
M.T., C.F.M., A.M.F.), and the Cardiology Section of the Department of
Medicine, Veterans Administration Medical Center and Baylor College of
Medicine, Houston, Tex (D.L.M.).
Correspondence to Dennis M. McNamara, MD, Division of Cardiology, University of Pittsburgh Medical Center, 200 Lothrop St, 558 Scaife Hall, Pittsburgh, PA 15213. E-mail mcnama{at}msx.upmc.edu
Background—Tumor
necrosis factor-
Methods and Results—TNFA and TNFB genotypes were
determined by the polymerase chain reaction–restriction fragment
length polymorphism technique. There were no differences in the TNF
allele frequencies between CHF (n=229; TNFA1/2=0.84/0.16,
TNFB1/2=0.33/0.67) and control subjects (n=139; TNFA1/2=0.84/0.16,
TNFB1/2=0.32/0.68). In 211 patients with CHF, circulating levels of
TNF-
Conclusions—Despite their association with other inflammatory
diseases, neither TNFA nor TNFB polymorphisms are related to the
presence of CHF or the elevation of circulating TNF-
© 1998 American Heart Association, Inc.
Brief Rapid Communications
Effects of Tumor Necrosis Factor Gene Polymorphisms on Patients With Congestive Heart Failure
(TNF-) is known to be elevated in
patients with congestive heart failure (CHF). Two biallelic
polymorphisms have been identified in the TNF gene locus: one in
the promoter region of TNF- (TNFA1/2), and the other in the first
intron of TNF-ß (TNFB1/2). Both TNFA2 and TNFB2 alleles are
associated with high TNF- production in vitro and
susceptibility to inflammatory diseases. Given the importance of
TNF- in the pathogenesis of CHF, we studied the prevalence of TNF
gene polymorphisms in CHF patients and the correlation of
genotypes to in vivo TNF- levels. and the soluble receptors type I and type II were measured by
ELISA: 6.18±3.59 pg/mL, 1768±761 pg/mL, and 4484±1750 pg/mL,
respectively. There were no correlations between TNFA or TNFB
genotypes and circulating levels of TNF- or its soluble
receptors in the CHF patients. . Thus, other
factors may be more important in determining the circulating levels of
TNF- in CHF.
Key Words: genetics • heart failure • immunology
This article has been cited by other articles:
 |
|
 |
|
  C Miceli-Richard, E Comets, C Verstuyft, R Tamouza, P Loiseau, P Ravaud, H Kupper, L Becquemont, D Charron, and X Mariette A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis Ann Rheum Dis, April 1, 2008; 67(4): 478 - 484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Stumpf, C Lehner, D Raaz, A Yilmaz, T Anger, W G Daniel, and C D Garlichs Platelets contribute to enhanced MCP-1 levels in patients with chronic heart failure Heart, January 1, 2008; 94(1): 65 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Kitsios and E. Zintzaras Genetic Variation associated with Ischemic Heart Failure: A HuGE Review and Meta-Analysis Am. J. Epidemiol., September 15, 2007; 166(6): 619 - 633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Koch, P. Hoppmann, E. Michou, V. Jung, A. Pfeufer, J. C. Mueller, C. Gieger, H.-E. Wichmann, T. Meitinger, A. Schomig, et al. Association of variants in the BAT1-NFKBIL1-LTA genomic region with protection against myocardial infarction in Europeans Hum. Mol. Genet., August 1, 2007; 16(15): 1821 - 1827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Sarzi-Puttini, F Atzeni, A Doria, L Iaccarino, and M Turiel Tumor necrosis factor-a, biologic agents and cardiovascular risk Lupus, September 1, 2005; 14(9): 780 - 784. [Abstract] [PDF]
|
|
|
|
 |
|
 N. Kawamura, T. Kubota, S. Kawano, Y. Monden, A. M. Feldman, H. Tsutsui, A. Takeshita, and K. Sunagawa Blockade of NF-{kappa}B improves cardiac function and survival without affecting inflammation in TNF-{alpha}-induced cardiomyopathy Cardiovasc Res, June 1, 2005; 66(3): 520 - 529. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Sekiguchi, X. Li, M. Coker, M. Flesch, P. M Barger, N. Sivasubramanian, and D. L Mann Cross-regulation between the renin-angiotensin system and inflammatory mediators in cardiac hypertrophy and failure Cardiovasc Res, August 15, 2004; 63(3): 433 - 442. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Feldman The emerging role of pharmacogenomics in the treatment of patients with heart failure Ann. Thorac. Surg., December 1, 2003; 76(6): S2246 - 2253. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Stumpf, C. Lehner, S. Eskafi, D. Raaz, A. Yilmaz, S. Ropers, A. Schmeisser, J. Ludwig, W. G. Daniel, and C. D. Garlichs Enhanced levels of CD154 (CD40 ligand) on platelets in patients with chronic heart failure Eur J Heart Fail, October 1, 2003; 5(5): 629 - 637. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Alikasifoglu, L. Tokgozoglu, T. Acil, E. Atalar, M. A. Oto, S. S. Kes, and E. Tuncbilek Tumor necrosis factor-{alpha} polymorphism in Turkish patients with dilated cardiomyopathy Eur J Heart Fail, March 1, 2003; 5(2): 161 - 163. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Machida, T. Kubota, N. Kawamura, H. Funakoshi, T. Ide, H. Utsumi, Y. Y. Li, A. M. Feldman, H. Tsutsui, H. Shimokawa, et al. Overexpression of tumor necrosis factor-alpha increases production of hydroxyl radical in murine myocardium Am J Physiol Heart Circ Physiol, February 1, 2003; 284(2): H449 - H455. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C G Densem, I V Hutchinson, N Yonan, and N H Brooks Tumour necrosis factor {alpha} gene polymorphism: a predisposing factor to non-ischaemic myocardial dysfunction? Heart, February 1, 2002; 87(2): 153 - 155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Szalai, G Fust, J Duba, J Kramer, L Romics, Z Prohaszka, and A Csaszar Association of polymorphisms and allelic combinations in the tumour necrosis factor-{alpha}-complement MHC region with coronary artery disease J. Med. Genet., January 1, 2002; 39(1): 46 - 51. [Full Text] [PDF]
|
|
|
|
 |
|
 P.P. Davey and H. Ashrafian New therapies for heart failure: is thalidomide the answer? QJM, May 1, 2000; 93(5): 305 - 311. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Feldman, A. Combes, D. Wagner, T. Kadakomi, T. Kubota, Y. You Li, and C. McTiernan The role of tumor necrosis factor in the pathophysiology of heart failure J. Am. Coll. Cardiol., March 1, 2000; 35(3): 537 - 544. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Charron, F Tesson, O Poirier, V Nicaud, M Peuchmaurd, L Tiret, F Cambien, P Amouyel, O Dubourg, J.-B Bouhour, et al. Identification of a genetic risk factor for idiopathic dilated cardiomyopathy. Involvement of a polymorphism in the endothelin receptor type A gene Eur. Heart J., November 1, 1999; 20(21): 1587 - 1591. [Abstract] [PDF]
|
|
|
|
 |
|
 N. Jenkins Tumor Necrosis Factor-{alpha} and Interleukin-10 Genotypes in Congestive Heart Failure Circulation, October 26, 1999; 100 (17): e84 - e84. [Full Text] [PDF]
|
|
|
|
|
|
M. Azzawi and P. Hasleton Tumour necrosis factor alpha and the cardiovascular system: its role in cardiac allograft rejection and heart disease Cardiovasc Res, September 1, 1999; 43(4): 850 - 859. [Full Text] [PDF]
|
|
|
|
|
|
S. Sasayama, A. Matsumori, and Y. Kihara New insights into the pathophysiological role for cytokines in heart failure Cardiovasc Res, June 1, 1999; 42(3): 557 - 564. [Full Text] [PDF]
|
|